



Société anonyme au capital de 1 611 465,60 euros
Headquarter : 72C route de Thionville - 57140 WOIPPY
552 064 933 R.C.S. METZ

AVAILABILITY OF THE 2025 ANNUAL FINANCIAL REPORT

Woippy, May 7, 2025 at 11:30 p.m.

ABL Diagnostics announces that it has made its 2025 Annual Financial Report available to the public and filed it with the Autorité des marchés financiers (AMF).

The report can be consulted on the ABL Diagnostics website: <https://www.abldiagnostics.com> under the section “Newsroom – Legal & Financial News”.

The Board of Directors, which met on April 30, 2025, approved the annual financial statements and decided to convene the shareholders to an Ordinary and Extraordinary General Meeting on June 30, 2026 at 11:00 a.m. at the offices of the law firm De Gaulle Fleurance & Associés, located at 9 rue Boissy d’Anglas, 75008 Paris.

About ABL Diagnostics (ABLD)

ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:

- Molecular polymerase chain reaction (PCR) detection – UltraGene, and
- Genotyping by DNA sequencing – DeepChek®.

ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.

ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

An expanding portfolio of microbiology products:

- HIV – Drug resistance testing, including a whole genome kit.
- SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
- Microbiome and taxonomy – 16s/18s RNA-based analyses.
- Other viral and bacterial targets – Comprehensive molecular assays.

Integrated Solutions

- Real-time syndromic PCR tests
- Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.
- MediaChek® – Clinical Sample Collection Kits.

ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.

Contact

ABL Diagnostics SA Société anonyme au capital de 1 611 465,60 euros Headquarters : 72C route de Thionville - 57140 WOIPPY 552 064 933 R.C.S. METZ	Tel : +33 (0)7 83 64 68 50 Email : info@abldiagnostics.com https://www.abldiagnostics.com/
--	---